Although HGV infection appears clinically benign in the vast majority of cases and although no causal relationship between HGV and hepatitis has been established, 6,7 some To study the prevalence and clinical features of hepatitis G virus (HGV)/GB virus C (GBV-C) infection in bone authors 8 have suggested that HGV is responsible for fulminant hepatitis and aplastic anemia.
Summary:
Although HGV infection appears clinically benign in the vast majority of cases and although no causal relationship between HGV and hepatitis has been established, 6 ,7 some To study the prevalence and clinical features of hepatitis G virus (HGV)/GB virus C (GBV-C) infection in bone authors 8 have suggested that HGV is responsible for fulminant hepatitis and aplastic anemia.
9,10 Furthermore, marrow transplantation (BMT), we examined frozen serum samples from 95 bone marrow allograft patients reports of chronic HGV carriers and of the high prevalence of HGV-positive blood donor populations 5,11,12 raise the for HGV/GBV-C RNA by RT-PCR. Twenty-eight out of 95 (29.5%) were positive and 14 of the HGV ϩ patients problem of a high risk of infection in multiply transfused and immunosuppressed patients. were already positive before transplantation. The mean numbers of blood donors to whom the HGV − and HGV + For these reasons, we have retrospectively studied the incidence and clinical features of HGV infection in 95 bone populations were exposed before BMT were not significantly different (Kruskal-Wallis test, P = 0.08, NS) but marrow allograft patients. did reveal that the HGV + population had been transfused more often. Moreover, all but one of the patients who were HGV + before graft, had had hematological diseases which needed heavy transfusion protocols sugMaterial and methods gesting, a role of blood products in HGV transmission. Fifty out of the 95 patients received Gammagard intravenous immunoglobulin (IVIG) batches suspected of Patients having transmitted HCV. However, no significant difference appeared between these recipients and those Ninety-five patients allografted in Saint-Louis Hospital (Paris), between 1985 and February 1996 with a follow-up receiving other IVIG. Despite their immunodeficiency, no clinical or biological evidence of liver disease potenof at least 6 months were studied. Eighty-three (87.4%) were grafted with family HLA-identical donors, 11 (11.6%) tially linked to HGV infection has as yet been observed. The clinical outcome, in terms of acute GVHD, chronic with unrelated HLA matched donors and one with cord blood (1%). The median survival was 3 years and 3 months GVHD or veno-occlusive disease was similar in HGV + and HGV − recipients suggesting the absence of adverse (range 7 months-11 years). There were 60 males and 35 females with a mean age of 26 years (range 2-59). Among effects of HGV infection on the early outcome of allogenic BMT. Long-term evolution remains to be prospecthese patients, 29.5% (28/95) had chronic myeloid leukemia, 34.7% (33/95) acute leukemia, 9.4% (9/95) Fanconi tively studied. Keywords: BMT; hepatitis G virus; GBV-C; GVHD; disease, 7.4% (7/95) non-Hodgkin lymphoma, 11.5% (11/95) severe aplastic anemia, 5.4% (5/95) myelodyspla-VOD sia, 1.05% (1/95) chronic lymphoid leukemia and 1.05% (1/95) paroxysmal nocturnal hemoglobinuria. After transplantation, recipients were followed-up at 3, Despite the discovery of HCV, 1 about 12% of post-trans-6 and 12 months or more often if needed. All patients were fusion hepatitis patients are seronegative for all known tested for HGV RNA at least 3 months after transplant and hepatotropic viruses.
2 Recently, cases of chronic hepatitis 36 out of 95 were also tested before transplant. were linked to the presence of genomic sequences of a Intravenous immunoglobulin (IVIG) was administered newly described RNA virus termed hepatitis G virus weekly from day −10 to day +100 at a dose of 500 mg/kg (HGV) belonging to the Flaviviridae family.
3-5 Obseri.v. according to the protocol published by Sullivan et al.
13
vations of blood recipients who were negative for HGV After day +100, patients presenting with a low serum RNA before transfusion and positive afterwards confirmed gammaglobulin level (Ͻ5 g/l) received IVIG at a dose of that this virus was transmitted by blood transfusion. 
Methods
Thirty-six patients were also tested for HGV RNA before the graft. Fourteen were found HGV RNA + and 22 HGV Serum HGV RNA was detected on frozen samples. RNA RNA − . The mean number of blood donors to which HGV + was extracted from 100 l of serum diluted with a solution and HGV − patients had been exposed before BMT was containing guanidinium thiocyanate. Nucleic acids were 39.5 ± 29 and 24 ± 28, respectively (Kruskal-Wallis test, isolated using phenol and chloroform and precipitated by P = 0.08, NS). isopropanol. cDNA synthesis was primed with random hexFifteen out of 28 HGV RNA + patients were retested at amers or specific primers. The resulting cDNA was examleast 3 months after the first positive detection. Four ined using a PCR procedure developed in the laboratory. patients became negative 3, 5, 8 and 18 months after the Four primer pairs were used, located in the NS3 region of first positive detection. For two patients, conversion of the GBV-C and in the NS5a, NS5b and 5′ non-coding (5′-HGV PCR result was confirmed on another serum sample NCR) regions of HGV genome. The NS3 primers were G9 and the death of the other two patients precluded retesting. (5′-TCYTTGATGATDGACTGTC-3′) for reverse For the other patients (11/15 or 73.3%), viremia was pertranscription, G8 (5′-TATGGGCATGGHATHCCYCT-3′, sistent (maximal duration of infection after detection was sense primer) and G11 (5′-TCYTTACCCCTRTAAT-37 months). AGGC-3′, anti-sense primer) for PCR, with amplification All patients had received IVIG post-graft; 50 of the 95 of a 140 base pair (bp) fragment; 3 the NS5a primers received Gammagard (Baxter, Deerfield, IL, USA) IVIG 77F (5′-CTCTTTGTGGTAGTAGCCAGAGAT-3′, sense batches suspected of having transmitted HCV (exposed primer) and 211R (5′-CGAATGAGTCAGAGGACGgroup) while 45 had received other IVIG batches; 16 of 50 GGGTAT-3′, anti-sense primer) amplified a 156 bp frag-(32%) and 12 of 45 (26.7%) were found positive for HGV ment; the NS5b primers GV57 (5′-GGACTTCCGGAT-RNA in the exposed and the unexposed groups, respect-AGCTGARAAGCT-3′, sense primer) and 4512MF (5′-ively (NS). Clinical outcome in terms of acute graft-versus-GCRTCCACACAGAAGGCGCA-3′, anti-sense primer) host disease (GVHD) (grade 0 vs I-IV), severe acute amplified a 165 bp fragment; 5 the 5′-NCR primers were (5′-GVHD (grade 0-I vs II-IV), chronic GVHD or veno-CGGCCAAAAGGTGGTGGATG-3′, sense primer and 5′-occlusive disease, was similar in the HGV + and HGV − CGACGAGCCTGACGTCGGG-3′, anti-sense primer) patients (Table 1) . which amplified a 166 bp fragment. In these sequences, R Among the 95 patients, 29 had liver complications: 28 denotes A or G, Y denotes C or T, D denotes A or G or hepatic GVHD and one cirrhosis. The cirrhosis followed T, H denotes A or C or T. PCR was performed on a Perkinthe HCV infection. Seven out of the 28 (25%) with hepatic Elmer (Norwalk, CT, USA) 9600 thermocycler for 45 GVHD were HGV + against 21 out of the 67 (31.3%) cycles consisting of denaturation at 94°C for 30 s, patients without hepatic GVHD (NS). annealing at 55°C for 30 s and extension at 72°C for 30 s Eight out of 28 (28.6%) HGV + patients and 31 out of 67 followed by an extension cycle at 72°C for 1 min. PCR (46%) HGV − patients had elevated levels of transaminases products were separated by agarose gel electrophoresis and (NS) ( Table 1) . visualized by ethidium bromide staining. This procedure was validated by a French multicentre quality control study.
14 Discussion HCV RNA detection was performed by an amplicor HCV kit (Roche Diagnostic Systems, Basel, Switzerland)
The recently cloned HGV 5 is closely related to GBV-C 4 in which amplified HCV RNA in a single tube reaction with terms of the high nucleotide and amino acid homology the single thermally stable enzyme rTth DNA polymerase. 15 between these two viruses. Our data showing a GBV-C Serum ALT level was determined by an automated viremia systematically associated with a HGV viremia are method and expressed in international units (IU)/l. The consistent with this observation. upper limit of normal ALT was 30 IU/l for women and 40
We have observed a high prevalence of HGV infection IU/l for men.
in the allograft population (28/95 or 29.5%). The observed prevalence is consistent with previous studies in multiply Statistical analysis transfused patients. 11, 16 However, this value is less significant than expected. Indeed, the mean blood donor exposure Results were expressed as mean ± 1 s.d. or as percentages per BMT in our patients was 67 donors ± 58 (range 12-with their 95% confidence intervals (CI) calculated accord-252) and according to the high frequency of HGV RNA ing to normal distribution. χ 2 test, Fisher exact test or nondetection in French blood donors (4.2%), 17 we expected a parametric test (Kruskal-Wallis test) were used for the larger number of contaminated recipients. This suggests comparison of categorical data.
that, due to individual susceptibility/resistance or to variable viral load in blood products, a large number of recipients may eliminate the virus or recover from an acute infecResults tion.
The persistent infection rate (Ͼ6 months) of acute GBVTwenty-eight patients out of 95 were positive for HGV RNA (29.5%, 95% confidence intervals = 20.3-38.7). The C infection acquired after blood transfusion was estimated in non-immunosuppressed patients (cardiac surgery) to be HGV + and HGV − populations were similar with respect to sex (P = 0.18, NS) and age (P = 0.68, NS) ( Table 1) . Three 36%. 18 In our series, among the 15 HGV RNA + patients with a follow-of, four became negative and the others were coinfected with HCV. 
NS NS NS NS NS NS NS NS (P = 0.68) (P = 0.18) (P = 0.18) (P = 0.5) (P = 0.5) (P = 0.3) (P = 0.67) remained infected, resulting in a rate of persistent infection in our population. However, long-term evolution remains to be prospectively studied. of 73.3% which is much higher than in non-immunosuppressed patients. One hypothesis is that the profound immunodeficiency of our patients may increase the risk of chronic HGV infection.
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